Praneeth R. Kuninty
Enschede, OV 7500AE, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Engineered cyclic peptide targeting ITGA5 disrupts tumor-stroma interaction to overcome desmoplasia and resistance in pancreatic ductal adenocarcinoma.
Journal: Acta pharmaceutica Sinica. B
Published: February 25, 2025
Cancer immune therapy using engineered ‛tail-flipping' nanoliposomes targeting alternatively activated macrophages.
Journal: Nature communications
Published: February 01, 2021
ITGA5 inhibition in pancreatic stellate cells attenuates desmoplasia and potentiates efficacy of chemotherapy in pancreatic cancer.
Journal: Science advances
Published: March 08, 2019
Reprogramming tumor stroma using an endogenous lipid lipoxin A4 to treat pancreatic cancer.
Journal: Cancer letters
Published: September 10, 2017
Anti-microRNA targeting using peptide-based nanocomplexes to inhibit differentiation of human pancreatic stellate cells.
Journal: Nanomedicine (London, England)
Published: May 20, 2017
Stroma-regulated HMGA2 is an independent prognostic marker in PDAC and AAC.
Journal: British journal of cancer
Published: September 22, 2016
MicroRNA Targeting to Modulate Tumor Microenvironment.
Journal: Frontiers in oncology
Published: October 19, 2015
SAINT-liposome-polycation particles, a new carrier for improved delivery of siRNAs to inflamed endothelial cells.
Journal: European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V
Published: July 07, 2014
Showing 1-10 of 10
Last Updated: 09/26/2026